Transparency notification BlackRock, Inc.

• Notification referring to situation on 13 January 2020
• Threshold crossed: 5%
• Latest holding: 4.91%

Brussels (Belgium), 20 January 2020 – 20:00 (CET) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 14 January 2020.

BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights by its affiliates, both its holding of UCB shares with voting rights and its total holding in voting rights of UCB have decreased and have crossed downwards the 5% threshold on 13 January 2020.

On 13 January 2020, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 412 691 UCB shares with voting rights (versus 9 927 826 shares in its previous notification), representing 4.84% of the total number of shares issued by the company (194 505 658) (versus 5.10% in its previous notification), as well as 140 713 equivalent financial instruments (versus 153 082 in its previous notification) representing 0.07% of the total number of shares issued by the company (versus 0.08% in its previous notification).

2. Content of the notification

• Reason for the notification: Acquisition or disposal of voting securities or voting rights.
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement:

• Chain of controlled undertakings through which the holding is effectively held:
  Please see the full chain of control in the ‘Chain of Control’ tab.

• Additional information:
  The disclosure obligation arose due to total holdings in voting rights for BlackRock, Inc. going below 5%. Additionally, voting rights attached to shares for BlackRock, Inc went below 5%.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte     

Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com
 
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news